Prior malignancy within the past 3 years except non-melanoma skin cancer or other localized cancer treated with curative intent
Other active malignancy, except non-melanomic skin cancer
Curatively treated non-melanoma skin malignancy
Curatively resected non-melanoma skin cancer;
Diagnosed with or received anti-cancer therapy for another primary malignancy within 3 years prior to entry (except for non-melanoma skin cancer or in situ cancers)
Currently active other malignancy other than non-melanoma skin cancer.
Previous or concurrent malignancy other than non-melanoma skin cancer within 5 years of diagnosis of prostate cancer
Known active invasive malignancy except for renal cell carcinoma and/or non-melanoma skin cancer
Any concurrent malignancy, except non-melanoma skin cancer
Second malignancy that is currently clinically significant or required active intervention during the period of 12 months prior to Screening, except early stage non-melanoma skin cancer treated with curative intent.
Other malignancy, except non-melanoma skin cancer, that is active or has a >= 30% probability of recurrence within 12 months
Active malignancy (with the exception of non-melanoma skin cancer), including relapse or progression of the underlying disease for which qualifying transplant was performed
Concomitant active malignancy that would be expected to require chemotherapy within 3 years of transplant (other than non-melanoma skin cancer)
Evidence of another malignancy, exclusive of a skin cancer that requires only local treatment
Any known prior malignancy (not including non-melanoma skin cancers), unless treated with curative intent
Known second primary or prior malignancy diagnosed within 5 years of study start date (other than previously treated non-melanoma skin cancer)
Other malignancy, except non-melanoma skin cancer, that is active or has a >/= 30% probability of recurrence within 12 months.
Adequately treated non-melanoma skin cancer OR
Any malignancy that required treatment (except non-melanoma skin cancer, or histologically confirmed complete excision of carcinoma in situ), within 2 years prior to study drug administration.
Previous or concurrent history of non-pancreatic malignancy except for non-melanoma skin cancer.
Unstable medical condition (e.g., another malignancy requiring treatment, malignant hypertension, poorly controlled diabetes, another cancer except for fully excised non-melanoma skin cancer)
Any other malignancy which has been active or treated within the past three years, with the exception of cervical intra-epithelial neoplasia and non-melanoma skin cancer
Prior malignancy (except non melanoma skin cancer) within 3 years
Other malignancy, except non-melanoma skin cancer, with a >= 30% probability of death within 24 months
History of malignancy within the last 3 years, with the exception of non-melanoma skin cancers and superficial bladder cancer
Prior malignancy within 5 years of enrollment excluding non?melanoma skin cancer or cervical carcinoma after curative resection, not requiring chemotherapy
Any known additional malignancy (with exception of non-melanoma skin cancer, in-situ breast cancer or a malignancy diagnosed >= 3 years ago and with no evidence of requiring active treatment)
Concurrent malignancy other than non-melanoma skin cancer
Active non-hematologic or lymphoid malignancy other than AML treated with immuno- or chemotherapy within the previous 12 months except active non-melanoma, non-invasive skin cancer will be allowed.
Any concurrent malignancy other than non-melanoma skin cancer, non-invasive bladder cancer, early stage prostate cancer, or carcinoma in situ of the cervix; patients with a previous non-pancreatic, non-periampullary malignancy without evidence of disease for > 5 years will be allowed to enter the trial
A malignancy [other than the one treated in this study] which required radiotherapy or systemic treatment within the past 5 years, or has a >= 30% probability of recurrence within 24 months (except for non-melanoma skin cancer or Ta urothelial carcinomas)
Any concurrent malignancy other than non-melanoma skin cancer, non-invasive bladder cancer, early stage prostate cancer, or carcinoma in situ of the cervix; patients with a previous non-pancreatic, non-periampullary malignancy without evidence of disease for > 5 years will be allowed to enter the trial
Other malignancy treated within the last 3 years (except non-melanoma skin cancer or low-grade superficial bladder cancer)
adequately treated non-melanoma skin cancer,
History of malignancy (other than non-melanoma skin cancer) within 5 years of enrollment
Any concurrent malignancy other than non-melanoma skin cancer, non-invasive bladder cancer, early stage prostate cancer, or carcinoma in situ of the cervix; patients with a previous non-pancreatic, non-periampullary malignancy without evidence of disease for > 5 years will be allowed to enter the trial
Other malignancy, except non-melanoma skin cancer, with a >= 30% probability of recurrence within 24 months
Any other malignancy that required treatment (except for non-melanoma skin cancer, or histologically confirmed complete excision of carcinoma in situ), within 2 years prior to study drug administration
History of another malignancy within the previous 5 years other than curatively treated non-melanoma skin cancer
Known history of malignancy diagnosed within 2 years other than non-melanoma skin cancer.
Participant has had another active malignancy within the past 3 years except for any cancer considered cured or non-melanoma carcinoma of the skin.
Secondary malignancy requiring active treatment except for non-melanoma skin cancer and superficial bladder cancer
Other active malignancy (with the exception of locally treated non-melanoma skin cancers)
Prior or current non-gynecologic or non-breast malignancy within 5 years except non-melanoma skin cancer
Known concurrent malignancy (except for non-melanoma skin cancer)
Non-melanoma skin cancer;
Matched Related Donor: Prior malignancy within the preceding five yrs, with the exception of non-melanoma skin cancers
Unrelated Donor: Prior malignancy within the preceding five yrs, with the exception of non-melanoma skin cancers
Diagnosis of another malignancy, with the exception of non-melanoma skin cancers within two years before the first dose, or previously treated for another malignancy with evidence of residual disease, with the exception of a synchronous endometrial cancer and non-melanoma skin cancers; carcinoma in situ will not be considered as malignancy
DONOR: Prior malignancy within the preceding 5 years, with the exception of non-melanoma skin cancers
No direct evidence of regional or distant metastases after appropriate staging studies; no synchronous primary or prior malignancy in past 2 years except non-melanoma skin cancer or in situ cancer
Have a concurrent active non-breast malignancy except for non-melanoma skin cancer
Participants has a prior history of malignancy, with the exception of non-melanoma skin cancer; participants with history of skin cancer must have 5 years elapse since that diagnosis, be in remission, and must not have received chemotherapy, immunotherapy, or radiation therapy
Other malignancy, except non-melanoma skin cancer, with a >= 30% probability of recurrence within 24 months
Other malignancy treated within the last 3 years (except non-melanoma skin cancer or low-grade superficial bladder cancer).
History of malignancy other than non-melanoma skin cancers within 5 years prior to\r\nstudy enrollment
The subject has had another diagnosis of malignancy requiring systemic treatment within the last two years, unless non-melanoma skin cancer, or superficial bladder cancer
Prior malignancy (except non-melanoma skin cancer) within 18 months of study entry NOTE: Patients must be in complete remission from prior malignancy in order to be eligible to enter the study.
Patients with an active second malignancy with the exception of non-melanoma skin cancer
Concurrent malignancy (other than non-melanoma skin cancer) diagnosed within the past 3 years or any currently active malignancy
DONOR: Prior malignancy within the preceding five years, with the exception of non-melanoma skin cancers
Prior malignancy (except non-melanoma skin cancer) within 3 years.
Patients who have had a history of non-cutaneous malignancy (other than non-melanoma skin cancer) in the previous 5 years are not eligible
Subjects with concurrent additional malignancy (with exception of non-melanoma skin cancers and superficial bladder cancer or malignancy within last 3 years)
Subject has another past or active malignancy which requires treatment. Prior carcinoma in situ or non-melanoma skin cancer after curative resection are permitted.
Active second malignancy other than non-melanoma skin cancer
non-melanoma skin cancer
Diagnosed or treated for another malignancy within 3 years prior to study enrollment, with the exception of complete resection of non-melanoma skin cancer, or an in situ malignancy
Curatively resected non melanoma skin cancer.
Malignancy within last 5 years except non-melanoma skin cancer.
Other active malignancy, except non-melanoma skin cancer and superficial bladder cancer
History of other malignancy within the past 3 years (except non-melanoma skin cancer)
Previously diagnosed with another malignancy, within the past two years with the exception of non-melanoma skin cancers or non-invasive bladder cancer
Any malignancy that required treatment, or has shown evidence of recurrence (except for soft tissue sarcoma, non-melanoma skin cancer, or histologically confirmed complete excision of carcinoma in situ) during the 5 years prior to randomization.
Prior malignancy (except non-melanoma skin cancer) within 3 years
Malignancy other than nonmelanoma skin cancer
Presence of other malignant diseases, except non-melanoma skin care
Had a malignancy, other than prostate or skin cancer (except malignant melanoma), within 5 years,
Development of invasive subsequent malignancy after HCT other than non-melanoma skin cancer, in the past two years
Any active malignancy (unrelated, non-hematological malignancy) diagnosed within the past 12 months of starting the study drug (other than curatively treated carcinoma-in-situ of the cervix or non-melanoma skin cancer)
History of any other malignancy treated within the past 3 years (other than non-melanoma skin cancer)
History of any other malignancy treated within the past 3 years (other than non-melanoma skin cancer)
No prior history of malignancy other than non-melanoma skin cancer (patient)
Prior history of malignancy other than non-melanoma skin cancer (patient)
Have a concurrent active non-breast malignancy except for non-melanoma skin cancer
Participants may have a personal history of non-ovarian malignancy, but must: a) be without evidence of disease at enrollment b) remain premenopausal c) have completed treatment (including surgery, chemotherapy, radiotherapy or hormonal therapy) > 3 months prior to enrollment (other than non-melanoma skin cancer)
Active malignancy; exception: non-melanoma skin cancers cancer(s) for which diagnosis and treatment was completed >= 3 years prior to pre-registration
Patients with concurrent invasive malignancy other than non-melanoma skin cancer or cervical intraepithelial neoplasia unless the treating physician considers it unlikely to impact the clinical outcome of the patient
Have received chemotherapy and/or radiation for any malignancy (excluding non-melanoma skin cancer and cancers confined to organs with removal as only treatment) in the past 2 years; ongoing adjuvant hormonal therapy for breast cancer is allowed
Subjects with current or previous malignancy other than prostate or non-melanoma skin cancer;
Have received chemotherapy and/or radiation for any malignancy (excluding non-melanoma skin cancer and cancers confined to organs with removal as only treatment) in the past 5 years (preceding the time of registration)
Participants may have a personal history of non-ovarian malignancy, but must be without evidence of disease at enrollment and the patient must have completed treatment (including surgery, chemotherapy, or radiotherapy) > 3 months prior to enrollment (other than non-melanoma skin cancer); current or past selective estrogen receptor modulator (SERM) or aromatase inhibitor use is allowed
Women who have been treated with chemotherapy for prior malignant disease or currently have an untreated malignancy other than non-melanoma skin cancer
HEALTHY VOLUNTEER: A history of neoplastic disease, with the exception of non-melanoma skin cancer
Prior history of any other malignancy within last 2 years, other than non-melanoma skin carcinoma
For melanoma patients, if patients have a history of malignancy other than melanoma and other skin cancers in the past five years, their inclusion is up to the discretion of the physician
Concurrent malignancy other than non-melanoma skin cancer
Other malignancy, except non-melanoma skin cancer, with a >= 30% probability of recurrence within 12 months
Any malignancy other than non-melanoma cell skin cancer, unless no evidence of disease for a minimum of 5 years
Patient cannot have received treatment for any malignancy, with the exception of non-melanoma skin cancer, in the past 5 years
Adequately treated non-melanoma skin cancer OR
Any other malignancy known to be active or treated within 3 years of start of screening, except cervical intra-epithelial neoplasia and non-melanoma skin cancer
Other malignancy, except non-melanoma skin cancer, with a >= 30% probability of recurrence within 24 months
History of another malignancy within the previous 5 years other than curatively treated non-melanoma skin cancer
Patients who have had a history of non-cutaneous malignancy in the previous 5 years are not eligible; exception: patients with history of non-melanoma skin cancer are eligible
Any malignancy other than non-melanoma cell skin cancer, unless no evidence of disease for a minimum of 5 years
